DRUG — Bright Minds Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$6.56m
- -CA$0.15m
- 16
- 32
- 25
- 13
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -0.079 | -0.48 | -8.65 | -15 | -7.37 |
Depreciation | |||||
Non-Cash Items | 0 | 0.161 | 0.657 | 0.648 | 1.22 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.037 | 0.031 | 0.675 | 0.724 | -0.942 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -0.042 | -0.288 | -7.32 | -13.6 | -7.02 |
Financing Cash Flow Items | — | — | -1.79 | -0.8 | -0.027 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.122 | 1.01 | 26.1 | 5.2 | 2.19 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.08 | 0.72 | 19 | -8.13 | -4.88 |